Vir Biotechnology Inc
VIR5.095USD
+0.065+1.29%
交易中 （美東）報價延遲15分鐘
703.43M總市值
虧損本益比TTM
關於 Vir Biotechnology Inc 公司
Vir Biotechnology, Inc. 是一家免疫學公司，專注於結合尖端技術來治療和預防嚴重傳染病和其他嚴重疾病。該公司的臨牀開發產品線包括針對丁型肝炎病毒 (HDV)、乙型肝炎病毒 (HBV) 和人類免疫缺陷病毒 (HIV) 的產品候選藥物。該公司的產品線中還有幾種臨牀前候選藥物，包括針對甲型和乙型流感、COVID-19、呼吸道合胞病毒和人類亞肺病毒 (RSV 和 MPV) 以及人乳頭瘤病毒 (HPV) 的產品。該公司的產品線包括 VIR-1949、VIR-7229、VIR-2981、VIR-8190 和 HIV Cure。該公司還致力於開發 tobevibart（一種也稱爲 VIR-3434 的單克隆抗體）和 Elebsiran（一種也稱爲 VIR-2218 的 siRNA），用於治療和抑制慢性 HDV。該公司的 Elebsiran 是一種正在研究的針對 HBV 的 siRNA，可以降低 HBsAg（一種 HDV 病毒生命週期所需的蛋白質）。
公司簡介
公司代碼VIR
公司名稱Vir Biotechnology Inc
上市日期Oct 11, 2019
CEODr. Marianne De Backer, Ph.D.
員工數量408
證券類型Ordinary Share
年結日Oct 11
公司地址1800 Owens Street
城市SAN FRANCISCO
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編94158
電話14159064324
網址https://www.vir.bio/
公司代碼VIR
上市日期Oct 11, 2019
CEODr. Marianne De Backer, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Robert J. (Bob) More
Mr. Robert J. (Bob) More
Independent Director
Independent Director
32.66K
-30.05%
Mr. Jeffrey S. (Jeff) Hatfield
Mr. Jeffrey S. (Jeff) Hatfield
Independent Director
Independent Director
23.81K
+50.61%
Dr. Marianne De Backer, Ph.D.
Dr. Marianne De Backer, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
19.03K
-80.53%
Ms. Saira Ramasastry
Ms. Saira Ramasastry
Independent Director
Independent Director
14.62K
+120.86%
Dr. Norbert W. Bischofberger, Ph.D.
Dr. Norbert W. Bischofberger, Ph.D.
Independent Director
Independent Director
8.00K
--
Ms. Vanina De Verneuil, J.D.
Ms. Vanina De Verneuil, J.D.
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
4.69K
-94.10%
Dr. Mark Eisner, M.D.
Dr. Mark Eisner, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Ms. Janet Napolitano, J.D.
Ms. Janet Napolitano, J.D.
Independent Director
Independent Director
--
--
Mr. Jason V. O'byrne
Mr. Jason V. O'byrne
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Dr. Vicki L. Sato, Ph.D.
Dr. Vicki L. Sato, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Robert J. (Bob) More
Mr. Robert J. (Bob) More
Independent Director
Independent Director
32.66K
-30.05%
Mr. Jeffrey S. (Jeff) Hatfield
Mr. Jeffrey S. (Jeff) Hatfield
Independent Director
Independent Director
23.81K
+50.61%
Dr. Marianne De Backer, Ph.D.
Dr. Marianne De Backer, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
19.03K
-80.53%
Ms. Saira Ramasastry
Ms. Saira Ramasastry
Independent Director
Independent Director
14.62K
+120.86%
Dr. Norbert W. Bischofberger, Ph.D.
Dr. Norbert W. Bischofberger, Ph.D.
Independent Director
Independent Director
8.00K
--
Ms. Vanina De Verneuil, J.D.
Ms. Vanina De Verneuil, J.D.
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
4.69K
-94.10%
收入明細
FY2024
暫無數據
地區USD
名稱
營收
佔比
United States
74.20M
0.00%
業務
地區
暫無數據
股東統計
更新時間: 6月5日 週四
更新時間: 6月5日 週四
持股股東
股東類型
持股股東
持股股東
佔比
SB Investment Advisers (UK) Limited
12.07%
BlackRock Institutional Trust Company, N.A.
10.40%
ARCH Venture Partners
9.34%
The Vanguard Group, Inc.
9.25%
GSK plc
6.19%
Other
52.75%
持股股東
持股股東
佔比
SB Investment Advisers (UK) Limited
12.07%
BlackRock Institutional Trust Company, N.A.
10.40%
ARCH Venture Partners
9.34%
The Vanguard Group, Inc.
9.25%
GSK plc
6.19%
Other
52.75%
股東類型
持股股東
佔比
Investment Advisor
28.96%
Investment Advisor/Hedge Fund
15.19%
Private Equity
13.70%
Venture Capital
10.23%
Hedge Fund
7.60%
Corporation
6.19%
Individual Investor
4.39%
Research Firm
1.90%
Foundation
1.13%
Other
10.73%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
530
124.95M
90.39%
-15.17M
2025Q1
571
125.80M
91.30%
-16.44M
2024Q4
568
122.14M
89.06%
-13.83M
2024Q3
554
118.76M
86.83%
-17.44M
2024Q2
572
119.53M
87.47%
-20.55M
2024Q1
564
122.68M
91.07%
-16.10M
2023Q4
577
121.87M
90.75%
-16.40M
2023Q3
578
123.93M
92.29%
-3.81M
2023Q2
574
125.10M
93.31%
+332.42K
2023Q1
568
121.09M
90.65%
+1.82M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
SB Investment Advisers (UK) Limited
16.68M
12.07%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
14.37M
10.4%
-298.87K
-2.04%
Mar 31, 2025
ARCH Venture Partners
12.92M
9.34%
--
--
Apr 01, 2025
The Vanguard Group, Inc.
12.78M
9.25%
-323.13K
-2.47%
Mar 31, 2025
GSK plc
8.55M
6.19%
--
--
Apr 01, 2025
State Street Global Advisors (US)
5.73M
4.14%
+652.43K
+12.86%
Mar 31, 2025
Scangos (George A)
3.78M
2.73%
-550.77K
-12.72%
Apr 01, 2025
Dimensional Fund Advisors, L.P.
2.68M
1.94%
+768.95K
+40.14%
Mar 31, 2025
Geode Capital Management, L.L.C.
2.30M
1.66%
+98.43K
+4.48%
Mar 31, 2025
OrbiMed Advisors, LLC
2.25M
1.63%
-970.37K
-30.15%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Genomics Immunology and Healthcare ETF
1.03%
Virtus LifeSci Biotech Clinical Trials ETF
0.87%
Global X Genomics & Biotechnology ETF
0.57%
ALPS Medical Breakthroughs ETF
0.47%
Invesco NASDAQ Future Gen 200 ETF
0.46%
Invesco S&P SmallCap Health Care ETF
0.33%
Hypatia Women CEO ETF
0.18%
SPDR S&P Biotech ETF
0.17%
Direxion Daily S&P Biotech Bull 3X Shares
0.1%
WisdomTree US SmallCap Quality Growth Fund
0.09%
查看更多
iShares Genomics Immunology and Healthcare ETF
佔比1.03%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.87%
Global X Genomics & Biotechnology ETF
佔比0.57%
ALPS Medical Breakthroughs ETF
佔比0.47%
Invesco NASDAQ Future Gen 200 ETF
佔比0.46%
Invesco S&P SmallCap Health Care ETF
佔比0.33%
Hypatia Women CEO ETF
佔比0.18%
SPDR S&P Biotech ETF
佔比0.17%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.1%
WisdomTree US SmallCap Quality Growth Fund
佔比0.09%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
